Science

Feb 28, 2025, 12:20

Myeloma Paper of the Day, February 28th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Updated long-term MAIA outcomes show PFS for DRd 61.9 vs 34.4 mos for Rd; median OS NR vs. 65.5 mos, 60-month OS rates 66.6% and 53.6%; MRD negativity 32.1% vs 11.1%, sustained MRD negativity (≥18 months) 16.8% vs 3.3%.”

“Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes”

Authors: Thierry Facon, Philippe Moreau, Katja Weisel, Fredrik Borgsten, Shaji Kumar et al.

More posts featuring Robert Orlowski.

cancer Fredrik Borgsten Katja Weisel MAIA Myeloma Myeloma Paper of the Day OncoDaily Oncology Philippe Moreau Robert Orlowski Shaji Kumar Thierry Facon

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more